Share
Dr. Pejvack Motlagh
.jpg "GENFIT Appoints Dr. Pejvack Motlagh as Chief Medical Officer")
GENFIT, a biopharmaceutical company focused on developing therapies for rare and life-threatening liver diseases, has appointed Dr. Pejvack Motlagh as its new Chief Medical Officer (CMO).
Dr. Motlagh will join GENFIT’s Executive Committee and assume responsibility for leading the company’s clinical development strategy and execution.
In his new role, Dr. Motlagh will oversee GENFIT’s Clinical Operations and Clinical Strategy functions, along with Biometrics and Pharmacovigilance. He will play a central role in shaping the company’s clinical development plans and advancing its pipeline to address significant unmet medical needs in liver diseases.
Dr. Motlagh brings more than 20 years of experience across the pharmaceutical and biotechnology sectors, with deep expertise in drug development strategy spanning multiple therapeutic areas. His background includes leadership roles across early-stage research, clinical development, and late-stage programs progressing toward commercialization.
Before joining GENFIT, Dr. Motlagh served as Chief Medical Officer at Egle Therapeutics, where he led clinical development activities for therapies targeting regulatory T cells in oncology and autoimmune diseases. Before that, he held the position of CMO at Mablink Biosciences, a biotechnology company developing next-generation antibody–drug conjugates (ADCs). Earlier in his career, Dr. Motlagh held senior clinical and medical leadership roles within large pharmaceutical organizations, contributing to the successful advancement of multiple compounds from early clinical phases through to market approval.
With his extensive industry experience and proven leadership in clinical development, Dr. Motlagh is expected to play a key role in strengthening GENFIT’s clinical programs and supporting the company’s mission to improve outcomes for patients with serious liver diseases.
